In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.
|Articles|January 28, 2010
supplement promo
In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
Advertisement
In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
This supplement and associated publication costs were funded by Genomic Health.
Advertisement
Related to this article
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5